Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs

References

• Band P. R., Deschamps M., Besner J.G, Leclaire R., Gervais P., Sanctis A. Phase I toxicologic study of lonidamine in cancer patients. Oncology 1984; 41(Suppl. 1)56–59
   PubMedGoogle Scholar
• Band P. R., Maroun J., Pritchard K., Stewart D., Coppin C. M., Wilson K., Wisenhauer E. A. Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treatment Reports 1986; 70: 1305–1310
   PubMedGoogle Scholar
• Besner J.-G, Leclaire R., Band P. R., Deschamps M., De Sanctis A. J., Catanese B. Pharmacokinetics of lonidamine after oral administration in cancer patients. Oncology 1984; 41(Suppl. 1)48–52
   PubMedGoogle Scholar
• Bleehen N. M., Walton M. I., Workman P. Interactions of hyperthermia with hypoxic cell sensitizers. Recent Results in Cancer Research 1988; 109: 136–148
   PubMedGoogle Scholar
• Chitnis M., Adwankar M. Potentiation of adriamycin cytotoxicity in P388 murine leukemia sensitive and resistant to adriamycin by use of lonidamine and hyperthermia. Tumori 1986; 72: 469–473
   PubMedGoogle Scholar
• Chitnis M., Juvekar A., Adwankar M., Advani S. Inhibition of DNA systhesis by lonidamine and hyperthermia in human chronic myeloid leukemia cells. Anticancer Research 1986; 6: 749–752
   PubMedGoogle Scholar
• Cioli V., Corradino C., De Martino C., Pasquini P., Rossi V., Silvestrini B. Pharmacologic investigations on lonidamine. Arzneimittel-Forschung 1984; 34: 455–460
   PubMedGoogle Scholar
• De Fabritiis P., Sandrelli A., Covelli A., Simone F., De Felice L., Pulsoni A., Zupi G., Mandelli F. In vitro pharmacological purging of human bone marrow is enhanced by lonidamine. Experimental and Molecular Pathology 1989; 50: 210–219
   PubMed Web of Science ®Google Scholar
• De Martino C., Malorni W., Accinni L., Rosati R., Nista A., Formisano G., Silvestrini B., Arcancia G. Cell membrane changes induced by lonidamine in human erythrocytes and T-lymphocytes, and Ehrlich ascites tumor cells. Experimental and Molecular Pathology 1987; 46: 15–30
   PubMed Web of Science ®Google Scholar
• Gibaldi M. Compartmental and noncompartmental pharmacokinetics. Biopharmaceutics and Clinical Pharmacokinetics, 4th edn. Lea & Febiger, Philadelphia 1991; 14–23
   Google Scholar
• Greco C., Cavaliere R., Giovanella B., Natali P. G., Zupi G. Effect of sequential application of hyperthermia and chemotherapy on the survival of a thermoresistant human melanoma cell line. Cancer Biochemistry-Biophysics 1987; 9: 223–232
   PubMedGoogle Scholar
• Hahn G. M., van Kersen I., Silvestrini B. Inhibition of the recovery from potentially lethal damage by lonidamine. British Journal of Cancer 1984; 50: 657–660
   PubMed Web of Science ®Google Scholar
• Honess D. J., Donaldson J., Workman P., Bleehen N. M. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. British Journal of Cancer 1985; 51: 77–84
   PubMed Web of Science ®Google Scholar
• Kim J. H., Kim S. H., Alfieri A., Young C. S., Silvestrini B. Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo. Oncology 1984a; 41(Suppl. 1)30–35
   PubMedGoogle Scholar
• Kim J. H., Alfieri A., Kim S. H., Young C. W., Silvestrini B. Radiosensitization of Meth-A fibrosarcoma in mice by lonidamine. Oncology 1984b; 41(Suppl. 1)36–38
   PubMedGoogle Scholar
• Kim J. H., Alfieri A. A., Kim S. H., Young C. W. Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Research 1986; 46: 1120–1123
   PubMed Web of Science ®Google Scholar
• Macy D. W., Macy C. A., Scott R. J., Gillette E. L., Speer J. F. Physiological studies of whole-body hyperthermia of dogs. Cancer Research 1985; 45: 2769–2773
   PubMed Web of Science ®Google Scholar
• Meyer R. E., Page R. L., Thrall D. E., Dewhirst M. W., Vose D. L. Determination of continuous atracurium infusion rate in dogs undergoing whole-body hypherthermia. Cancer Research 1986; 46: 5599–5601
   PubMed Web of Science ®Google Scholar
• Murray N., Shah A., Band P. Phase II study of lonidamine in patients with small cell carcinoma of the lung. Cancer Treatment Reports 1987; 71: 1283–1284
   PubMedGoogle Scholar
• Newman R. A., Dogramatzis D., Benvenuto J. A., Trevino M., Stephens L. C., Wondergem J., Strebel R., Baba H., Bull J. M. Effect of whole-body hyperthermia on pharmacokinetics and tissue distribution of doxorubicin. International Journal of Hyperthermia 1992; 8: 79–85
   PubMed Web of Science ®Google Scholar
• Ning S., Hahn G. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cell. in vitro. Cancer Research 1990; 50: 7867–7870
   PubMed Web of Science ®Google Scholar
• Page R. L., Macy D. W., Ogilvie G. K., Rosner G. L., Dewhirst M. W., Thrall D. E., Withrow S. J., McEntee M. C., Cline J. M., Heidner G. L., Novotney C. A., Gillette E. L. Phase III evaluation of doxorubicin and whole body hyperthermia in dogs with lymphoma. International Journal of Hyperthermia 1992; 8: 187–197
   PubMed Web of Science ®Google Scholar
• Page R. L., Meyer R. E., Thrall D. E., Dewhirst M. W. Cardiovascular and metabolic response of tumour-bearing dogs to whole body hyperthermia. International Journal of Hyperthermia 1987; 6: 513–525
   Google Scholar
• Price G. S., Page R. L., Riviere J. E., Cline J. M., Thrall D. E. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs. Cancer Chemotherapy and Pharmacology 1995, in review
   Google Scholar
• Raaphorst G. P., Feeley M. M., Heller D. P., Danjoux C. E., Martin L., Maroun J. A., Sanctis A. J. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells. Anticancer Research 1990; 10: 923–928
   PubMedGoogle Scholar
• Riviere J. E., Page R. L., Dewhirst M. W., Tyczkowska K., Thrall D. E. Effect of hyperthermia on cisplatin pharmacokinetics in normal dogs. International Journal of Hyperthermia 1986; 2: 351–358
   PubMedGoogle Scholar
• Riviere J. E., Page R. L., Rogers R. A., Chang S. K., Dewhirst M. W., Thrall D. E. Nonuniform alteration of cis-diamminedichloroplatinum(II) tissue distribution in dogs with whole body hyperthermia. Cancer Research 1990; 50: 2075–2080
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Lagoni R. K., Neville A. J., Hugander A., Schmitt C. L., Riggs C. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Research 1988; 48: 6587–6592
   PubMed Web of Science ®Google Scholar
• Rosbe K. W., Brann T. W., Holden S. A., Teicher B. A., Frei E. Effect of lonidamine on the cytotoxicity of four alkylating agent. in vitro. Cancer Chemotherapy and Pharmacology 1989; 25: 32–36
   PubMed Web of Science ®Google Scholar
• Serge G., Catanese B. Pharmacokinetics of lonidamine. Chemotherapy 1981; 27(Suppl. 1)77–84
   PubMedGoogle Scholar
• Silvestrini B., Hahn G. M., Cioli V., Martino C. Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumor systems. British Journal of Cancer 1983; 47: 221–231
   PubMedGoogle Scholar
• Steel R. G. D., Torrie J. H. Analysis of variance I: the one-way classification. Principles and Procedures of Statistics: A Biometrical Approach 2nd edn. McGraw-Hill, New York 1980a; 137–171
   Google Scholar
• Steel R. G. D., Torrie J. H. Comparisons involving two sample means. Principles and Procedures of Statistics: A Biometrical Approach 2nd edn. McGraw-Hill, New York 1980b; 86–121
   Google Scholar
• Steel R. G. D., Torrie J. H. Linear regression. Principles and Procedures of Statistics: A Biometrical Approach 2nd edn. McGraw-Hill, New York 1980c; 239–271
   Google Scholar
• Teicher B. A., Herman T. S., Holden S. A., Epelbaum R., Liu S., Frei E. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Research 1991; 51: 780–784
   PubMed Web of Science ®Google Scholar
• Thrall D. E., Page R. L., Dewhirst M. W., Meyer R. E., Hoopes P. J., Kornegay J. N. Temperature measurements in normal and tumor tissue of dogs undergoing whole body hyperthermia. Cancer Research 1986; 46: 6229–6235
   PubMed Web of Science ®Google Scholar
• Tura S., Cavo M., Gobbi M., Franchi P. Lonidamine in the treatment of chronic lymphoid leukemia. Oncology 1984; 41(Suppl. 1)90–93
   PubMedGoogle Scholar
• Walton M. I., Bleehen N. M., Workman P. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03–8799 in mice. British Journal of Cancer 1987; 55: 469–476
   PubMed Web of Science ®Google Scholar
• Weinerman B. H., Eisenhauer E. A., Besner J.G, Coppin C. M., Stewart D., Band P. R. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treatment Reports 1986; 70: 751–754
   PubMedGoogle Scholar
• Wilke A. V., Jenkins C., Milligan A. J., Legendre A., Frazier D. L. Effect of hyperthermia on normal tissue toxicity and on adriamycin pharmacokinetics in dogs. Cancer Research 1991; 51: 1680–1683
   PubMed Web of Science ®Google Scholar
• Young C. W., Currie V. E., Kim J. H., O' Hehir M. A., Farag F. M., Kinahan J. E. Phase I and clinical pharmacologic evaluation of lonidamine in patients with advanced cancer. Oncology 1984; 41(Suppl. 1)60–65
   PubMedGoogle Scholar
• Zupi G., Greco C., Laudonio N., Benassi M., Silvestrini B., Caputo A. In vitro and in vivo potentiation of lonidamine of the antitumor effect of adriamycin. Anticancer Research 1986; 6: 1245–1250
   PubMed Web of Science ®Google Scholar